

Certificate of Analysis

p53 (expressed in *E coli*)

Item # 14-952, 14-952-K, 14-952M

Parent Lot # WAD0330

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal cMyc and GST-tagged, recombinant, human p53 full length expressed in *E coli*. Purified using glutathione agarose and gel filtration. Purity 82% by SDS-PAGE and Coomassie blue staining. MW = 72kDa.

Formulation: 0.34mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 0–200nM of this lot of p53 was tested as a substrate capable of phosphorylation by DNA-PK, active (Eurofins cat# 14-950) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as p53 with the translated sequence listed on page three



Certificate of Analysis

Phosphorylation of p53 by DNA-PK, active

Reagents:

- 1 x Reaction Buffer:** 25mM HEPES pH8.0, 0.01% Brij-35, 1% Glycerol.
- Dilution Buffer:** 25mM HEPES pH8.0, 0.01% Brij-35, 1% Glycerol, 5mM DTT, 1mg/ml BSA
- ATP Solution (4x):** 400µM ATP, 40mM Magnesium Acetate.
- p53 (expressed in *E.coli*):** Dilute with 25mM HEPES pH8.0, 0.01% Brij-35, 1% Glycerol. Use 0–200nM per assay point.
- DNA-PK, active (Eurofins cat # 14-950):** Dilute with 25mM HEPES pH8.0, 0.01% Brij-35, 1% Glycerol, 5mM DTT, 1mg/ml BSA. Use 0.5ng per assay well.
- Stop Solution:** 12.5mM HEPES pH8.0, 0.005% Brij-35, 0.5% Glycerol, 250mM EDTA.
- Detection Mix:** 50mM HEPES pH7.0, 150mM NaCl, 267mM KF, 0.1% sodium cholate, 0.01% Tween 20, 0.0125% sodium azide, anti-phospho-p53 (Ser15)-K (CisBio 61P08KAE) 0.42ng/well, and anti-GST-d2 (CisBio 61GSTDLA) 25ng/well.

Suggested Assay Procedure (384 well plate format):

The volumes detailed below are suitable for a 384-well plate (e.g. Corning Costar 3573) using a 20µL reaction volume (30µL stopped volume).

Assay Procedure

- Add 10µl of 1 x reaction buffer per assay to wells.
- Add 2.5µl of (0–200nM) p53.
- Add 2.5µl (0.5ng) **DNA-PK, active**.
- Add 5µl of ATP mixture to initiate the reaction.
- Incubate for 30 minutes at room temperature.
- Stop the reaction by adding 5µl of the 12.5mM HEPES pH8.0, 0.005% Brij-35, 0.5% Glycerol, 250mM EDTA.
- Add 5µL Detection Mix
- It is recommended that the plate is sealed to minimize reduction in reaction volume. It is recommended that the plate is read after an overnight incubation following the termination of the reaction and addition of the Detection Mix.
- Measure HTRF ratio on an appropriate microplate reader according to the following parameters:

Excitation	330 - 380nm
Emission	665 - 667.5nm and 620 - 635nm
Counting Delay	50µsec
Counting window	(integration time) 400µsec

Refer to your instrument manufacturer for further guidance on measurement parameters recommended for HTRF.

Calculation:

HTRF Ratio is calculated as follows:

$$HTRF \text{ Ratio} = \left(\frac{\text{Emission at } 665nm}{\text{Emission at } 620nm} \right) \times 10000.$$

Certificate of Analysis

p53 Sequence Information

<u>Protein</u>	human p53
<u>Tags</u>	N-terminal cMyc and N-terminal GST
<u>Native sequence</u>	M240 of the recombinant protein is equivalent to M1 of human p53
<u>Accession number</u>	GenBank BC003596.1

Recombinant p53 amino acid sequence:

```

1 MEQKLISEED LSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL
61 EFPNLPYYID GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA
121 YSKDFETLKV DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL
181 DAFPKLVCFK KRIEAIPOID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD LVPRGSKEFM
241 EEPQSDPSVE PPLSQETFSD LWKLLPENNV LSPLPSQAMD DLMLSPDDIE QWFTEDPGPD
301 EAPRMPEAAP RVAPAPAAPT PAAPAPAPSW PLSSSVPSQK TYQGSYGFRL GFLHSGTAKS
361 VTCTYSPALN KMFCQLAKTC PVQLWVDSTP PPGTRVRAMA IYKQSQHMTE VVRRCPHHER
421 CSDSDGLAPP QHLIRVEGNL RVEYLDDRNT FRHSVVVPYE PPEVGSDCIT IHYNYMCNSS
481 CMGGMNRRIPI LTIITLEDSS GNLLGRNSFE VRVCACAGRDR RTEEENLRK KGEPHHELPP
541 GSTKRALPNN TSSSPQPKKK PLDGEYFTLQ IRGRERFEMF RELNEALELK DAQAGKEPGG
601 SRAHSSHLKS KKGQSTSRHK KLMFKTEGPD SD
  
```

Recombinant p53 nucleotide sequence:

```

1 atggaacaaa aattgatttc ggaagaagac ttgtccccta tactaggtta ttgaaaatt
61 aagggccttg tgcaaccac tgcacttctt ttggaatc ttgaagaaa atatgaagag
121 catttgatg agcgcgatga aggtgataaa tggcgaaca aaaagtttga attgggttg
181 gagtttccca atcttcctta ttatatgat ggtgatgta aattaacaca gtctatggcc
241 atcatacgtt atatagctga caagcacaac atgttgggtg gttgtccaaa agagcgtgca
301 gagatttcaa tgcttgaagg agcggttttg gatattgat acggtgtttc gagaattgca
361 tatagtaaag actttgaaac tctcaaagtt gattttctta gcaagctacc tgaaatgctg
421 aaaatgttcg aagatcgttt atgtcataaa acatatttaa atggtgatca tgtaaccat
481 cctgacttca tgttgatga cgctcttgat gttgttttat acatggacc aatgtgctg
541 gatgcttcc caaaattagt ttgttttaaa aaacgtattg aagctatccc acaaattgat
601 aagtacttga aatccagcaa gtatatagca tggcctttgc agggctggca agccactgtt
661 ggtggtgcg aacatcctcc aaaatcggat cctggtccgc gtggatccaa ggaattcatg
721 gaggagccgc agtcagatcc tagcgtcgag ccccctctga gtcaggaaac attttcagac
781 ctatggaaac tacttcctga aaacaacggt ctgtccccct tgccgtccca agcaatggat
841 gatttgatgc tgtccccgga cgatattgaa caatggttca ctgaagacc aggtccagat
901 gaagctccca gaatgccaga ggctgctccc cgcgtggccc ctgcaccagc agctcctaca
961 ccggcggccc ctgcaccagc cccctcctgg cccctgtcat cttctgtccc tcccagaaa
1021 acctaccagg gcagctacgg tttccgtctg ggcttcttgc attctgggac agccaagtct
1081 gtgacttgca cgtactcccc tgcccctcaac aagatgtttt gccaactggc caagacctgc
1141 cctgtgcagc tgtgggttga ttccacacc ccgcccggca cccgctccg cgccatggcc
1201 atctacaagc agtcacagca catgacggag gttgtgaggc gctgccccca ccatgagcgc
1261 tgctcagata gcgatggtct ggcccctcct cagcatctta tccgagtgga aggaaatttg
1321 cgtgtggagt atttggatga cagaaacact tttcgacata gtgtggtggt gccctatgag
1381 ccgctgagg ttggctctga ctgtaccacc atccactaca actacatgtg taacagttcc
1441 tgcatgggcg gcatgaaccg gaggcccatc ctcaccatca tcacactgga agactccagt
1501 ggtaatctac tgggacggaa cagctttgag gtgctgtgtt gtgctgtgc tgggagagac
1561 cggcgcacag aggaagagaa tctccgcaag aaaggggagc ctcaccacga gctgccccca
1621 gggagcacta agcagcact gcccaacaac accagctcct ctccccagcc aaagaagaaa
1681 cactggatg gagaatattt cacccttcag atccgtgggc gtgagcgtt cgagatgttc
1741 cgagagctga atgaggcctt ggaactcaag gatgcccagg ctgggaagga gccagggggg
  
```

Certificate of Analysis

1801 agcagggctc actccagcca cctgaagtcc aaaaagggtc agtctacctc ccgccataaa
1861 aaactcatgt tcaagacaga agggcctgac tcagactga

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 **Eurofins Pharma Discovery Services UK Limited** is an independent member of Eurofins Discovery Services